Prostate cancer gene therapy: Comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 4101-4109

  Hull, G W ^a   McCurdy, M A ^a   Nasu, Y ^a   Bangma, C H ^a   Yang, G ^a   Shimura, S ^a   Lee, H M ^a   Wang, J ^a   Albani, J ^a   Ebara, S ^a   Sato, T ^a   Timme, T L ^a   Thompson, T C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; VIRUS VACCINE;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; GENE THERAPY; IMMUNOCOMPETENT CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME; VIRUS EXPRESSION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, CD80; CANCER VACCINES; FLOW CYTOMETRY; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-12; KINETICS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033766179     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests
2. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer
3. Quality-of-life outcomes in men treated for localized prostate cancer
4. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
5. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
6. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer
7. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice
8. In situ gene therapy for prostate cancer
9. In situ gene therapy for adenocarcinoma of the prostate: A Phase I clinical trial
10. Molecular characterization of defective antigen processing in human prostate cancer
11. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
12. Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells
13. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
14. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression
15. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
16. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12
17. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma
18. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4
19. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum
20. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules
21. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma
22. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active interleukin-12
23. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression
24. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
25. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer
26. Tumour cell expression of B7 co-stimulatory molecules and interleukin-12 or granulocyte-macrophage colony stimulating factor induces a local antitumor response and may generate systemic protective immunity
27. Gene transfer to liver cancer cells of B7-1 plus interleukin 12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone
28. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
29. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
30. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment